Bioanalytical Services
 |
PharmaNet offers bioanalytical laboratory services through its subsidiaries: Anapharm, Anapharm Europe, Keystone Analytical and Taylor Technology.
Together, they offer over 1000 bioanalytical validated methods for one or more analytes from human or animal matrices.
Our laboratories can develop and validate custom (or project-specific) ELISAs or ligand-binding assays and can also develop and validate cell-based assays.
We are also actively working on developing proprietary methods that are not currently included in this list.
You may also view our list of biomarkers below.
List of BioMarkers
(Click here)
Contact us for more details.
(In alphabetically order)
Together, they offer over 1000 bioanalytical validated methods for one or more analytes from human or animal matrices.
Our laboratories can develop and validate custom (or project-specific) ELISAs or ligand-binding assays and can also develop and validate cell-based assays.
We are also actively working on developing proprietary methods that are not currently included in this list.
You may also view our list of biomarkers below.
List of BioMarkers
(Click here)
Contact us for more details.
(In alphabetically order)
 |
 |
 |
 |
 |
| Lacidipine | Cardiovascular | LC/MS/MS | 20-5000 pg/mL | Human EDTA Plasma |
| Lamivudine | Infectious Disease | LC/MS/MS | 10-5000 ng/mL | Human EDTA Plasma |
| Lamotrigine | Central Nervous System Agents | LC/MS | 50-10000 ng/mL | Human EDTA Plasma |
| Lansoprazole | Gastrointestinal | LC/MS/MS | 2.5-2000 ng/mL | Human EDTA K3 Plasma |
| Lansoprazole | Gastrointestinal | LC/MS/MS | 2-2000 ng/mL | Human EDTA Plasma |
| Lapatinib | TBD | LC/MS/MS | 100-10000 ng/mL | Human EDTA Plasma |
| L-Citrulline | Cardiovascular | LC/MS/MS | 150-10000 ng/mL | Human EDTA Plasma |
| L-Citrulline | Cardiovascular | LC/MS/MS | 150-10,000 ng/mL | Human EDTA Plasma |
| L-Citrulline | Cardiovascular | LC/MS/MS | 500-20,000 ng/mL | Rat EDTA Plasma |
| L-Citrulline | Cardiovascular | LC/MS/MS | 500 - 20000 ng/mL | Rat EDTA Plasma |
| Leflunomide metabolite (A77 1726) | Immunology | LC/MS/MS | 40-16000 ng/ml | Human EDTA K3 plasma |
| Lercanidipine | Cardiovascular | LC/MS/MS | 25-10000 pg/mL | Human EDTA Plasma |
| Letrozole | Oncology | LC/MS/MS | 0.50-200 ng/mL | Human K3 EDTA Plasma |
| Leukotriene B4 | Miscellaneous | LC/MS/MS | 0.5-250 ng/mL | Rat EDTA Plasma |
| Leukotriene B4 | Miscellaneous | LC/MS/MS | 25-12500 pg/mL | Human EDTA Plasma |
| Leukotriene B4 | Miscellaneous | LC/MS/MS | 25-12500 pg/mL | Human Urine |
| Leuprolide | Oncology OR Endocrinology | LC/MS/MS | TBD | Human EDTA Plasma |
| Levetiracetam | Central Nervous System Agents | LC /MS/MS | 100-40000 ng/mL | Human EDTA Plasma |
| Levodopa | Central Nervous System Agents | LC/MS/MS | 10-6000 ng/mL | Human EDTA Plasma |
| Levofloxacin | Infectious Disease | HPLC/FLR | 100-50000 ng/mL | Human Serum/Sputum Homogenate |
| Levofloxacin | Infectious Disease | HPLC/FLR | 200-100000 ng/mL | Human Urine |
| Levomethadone; Dextromethadone | Miscellaneous | LC/MS/MS | 0.5-100 ng/mL | Human Lithium Heparinized Plasma |
| Levonorgestrel | Endocrinology | LC/MS/MS | 125-25000 pg/mL | Human EDTA Plasma |
| Levothyroxine (T4) | Endocrinology | RIA | 10-250 ng/mL | Human Serum |
| Lidocaine | Pain | LC/MS/MS | 1-250 ng/mL | Human EDTA K3 Plasma |
| Linezolid | Infectious Disease | LC/MS/MS | 100-20000 ng/mL | Human EDTA Plasma |
| Liothyronine | Endocrinology | RIA | 0.5-25 ng/mL | Human Serum |
| Lisinopril | Cardiovascular | LC/MS/MS | 0.5-50 ng/mL | Human EDTA Plasma |
| Loperamide | Gastointestinal | LC/MS/MS | 50-5000 pg/mL | Human EDTA Plasma |
| Loperamide | Gastointestinal | LC/MS/MS | 25-2500 pg/mL | Human EDTA Plasma |
| Loratadine; Descarboethoxy Loratadine | Respiratory | LC/MS/MS | 20-20000 pg/mL | Human EDTA Plasma |
| Lorazepam | Central Nervous System Agents | LC/MS/MS | 1-75 ng/mL | Human EDTA K3 Plasma |
| Lorazepam | Central Nervous System Agents | LC/MS/MS | 0.1-30 ng/mL | Human EDTA K3 Plasma |
| Lorazepam | Central Nervous System Agents | LC/MS/MS | 0.5-100 ng/mL | Human Heparinized Plasma |
| Losartan | Cardiovascular | LC/MS/MS | 2-800 ng/mL | Human EDTA K3 Plasma |
| Losartan | Cardiovascular | LC/MS/MS | 2-500 ng/mL | Human Plasma |
| Losartan; Losartan Carboxy Acid | Cardiovascular | LC/MS/MS | 2-800 ng/mL | Human Lithium Heparinized Plasma |
| Losartan; Losartan Carboxy Acid | Cardiovascular | LC/MS/MS | 2-800 ng/mL | Human EDTA Plasma |
| Losartan; Losartan Carboxy Acid | Cardiovascular | LC/MS/MS | 1-2000 ng/mL | Human EDTA Plasma |
| Lovastatin | Cardiovascular | LC/MS/MS | 200-10000 pg/mL | Human EDTA Plasma |
| Lovastatin Hydroxy acid | Cardiovascular | LC/MS/MS | 200-10000 pg/mL | Human EDTA Plasma |
| Luteinizing Hormone (LH) | Endocrinology | RIA | 3-200 mIU/mL | Human Serum |